Daphne V. Huizing-De Vries

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.

PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 12, 2026

Successful palliative hypofractionated radiotherapy with superficial hyperthermia for heavily pretreated cutaneous breast cancer lesions.

Successful palliative hypofractionated radiotherapy with superficial hyperthermia for heavily pretreated cutaneous breast cancer lesions.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: February 06, 2026

PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.

PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.

Journal: Journal of neuroendocrinology

Published: January 21, 2025

Towards harmonized holmium-166 SPECT image quality for dosimetry: a multi-center, multi-vendor study.

Towards harmonized holmium-166 SPECT image quality for dosimetry: a multi-center, multi-vendor study.

Journal: EJNMMI physics

Published: July 31, 2024

Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.

Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.

Journal: Clinical nuclear medicine

Published: March 11, 2024

Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model.

Journal: EJNMMI physics

Published: September 25, 2023

Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).

Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).

Journal: European journal of nuclear medicine and molecular imaging

Published: August 15, 2023

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.

The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 01, 2023

Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial).

Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial).

Journal: BMC cancer

Published: April 21, 2022

Post-PRRT scans: which scans to make and what to look for.

Post-PRRT scans: which scans to make and what to look for.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: February 07, 2022

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient's therapy course.

Journal: PloS one

Published: March 02, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026